EDUCATION
Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications
.jpg)
The extraordinary advancements made over the past several years in the clinical management of cancer have ushered in a new era of optimism for those afflicted with many cancer types. However, these advancements have also created a highly complex environment for healthcare providers and diagnostic laboratory personnel.
This webinar series will efficiently describe emerging and evolving biomarkers. Read more about this series in this JMD article.
LEARNING OBJECTIVES
- Describe the biological principles that underlie the pathogenicity of each biomarker, including the cellular signaling pathways and cellular processes involved.
- Discuss the appropriate technical approaches and platforms for molecular diagnostic testing for each biomarker.
- Outline the strengths and limitations of described testing approaches.
- Apply biomarker information so as to order appropriate testing and interpret biomarker status results within a clinical context.
Supported by an educational grant from AstraZeneca
LIVE WEBINARS
Registration coming soon for our next webinar in June 2026!
| Date Recorded | Webinar Title | Video | Paper |
|---|---|---|---|
| 6/30/2020 | MGMT: Updated Perspectives, Laboratory Considerations, and Clinical Implications | Retired | |
| 7/21/2020 | HRD: Recent findings, laboratory considerations and clinical implications | Retired | |
| 9/29/2020 | METex14: Recent findings, laboratory considerations and clinical implications | Retired |  |
| 12/8/2020 | NTRK: Recent findings, laboratory considerations and clinical implications | Retired | |
| 4/15/2021 | ERBB2 (HER2) in Colorectal Cancer: Recent findings, laboratory considerations and clinical implications |  |
|
| 6/29/2021 | Myeloid Malignancy MRD: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 10/12/2021 | KRAS: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 1/25/2022 | Methylation Profiling: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 4/7/2022 | B-cell Receptor and T-Cell Receptor Sequencing: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 5/3/2022 | Mutational Signatures in Cancer: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 9/22/2022 | Molecular diagnostic and clinical perspectives on microsatellite instability testing for cancer | |
|
| 12/6/2022 | EGFR Exon 20 Insertions: Recent Findings, Laboratory Considerations, and Clinical Implications | |
|
| 4/12/2023 | Being eNRGy Conscious: Understanding NRG1 Fusions | |
|
| 9/28/2023 | FLT3 mutations and AML: Recent findings, laboratory considerations, and clinical implications | |
|
| 3/14/2024 | Oncogenic RET Fusions: Biology, Testing, and Treatment | |
|
| 6/20/2024 | TP53 Mutations in Myeloid Neoplasms: From Clonal Hematopoiesis to Acute Leukemia | |
|
| 10/31/2024 | Molecular Classification and Predictive Biomarkers in Endometrial Carcinoma | |
|
| 1/30/2025 | Germline Testing in Cancer Patients: Molecular Diagnostic Considerations and Clinical Implications | |
|
| 4/1/2025 | Molecular International Prognostic Scoring System (IPSS-M) in Routine Diagnostics | |
|
| 6/26/2025 | STK11 and KEAP1 Mutations in Lung Cancer | |
|
| 10/9/2025 | Cell-free DNA (cfDNA) from Cerebrospinal Fluid (CSF) for Diagnosis and Molecular Testing of Brain Tumors | |
|
| 3/16/2026 | Monitoring of Patients Receiving Menin Inhibitors for Acute Leukemia | |
CONTINUING EDUCATION CREDIT INFORMATION
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™per webinar. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit per webinar. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
CONTENT COMMITTEE
This webinar series on Emerging and Evolving Biomarkers (EEB) is planned and coordinated by the Emerging and Evolving Biomarkers Content Committee:
Pawel Mroz, M.D., Ph.D. (Chair 2026)
University of Minnesota Medical School
Rena Xian, M.D.
The Johns Hopkins School of Medicine
Fei Dong, M.D.
Stanford University
Erica Vormittag-Nocito, M.D.
ACL Laboratories
And supported by the AMP Training & Education Committee
